Norway biotech Ultimovacs plans IPO to develop cancer drug

Published 5y ago

OSLO (Reuters) – Norway’s Ultimovacs plans to raise around 700 million Norwegian crowns ($82 million) in an initial public offering in early 2019 to help fund the development of its immunotherapy cancer drug. “Our main investors are positive and will take a si... More »